Is UNII-F41401512X Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-F41401512X? Is UNII-F41401512X safe for nursing mother and child? Does UNII-F41401512X extracts into breast milk? Does UNII-F41401512X has any long term or short term side effects on infants? Can UNII-F41401512X influence milk supply or can UNII-F41401512X decrease milk supply in lactating mothers?

• DrLact safety Score for UNII-F41401512X is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of UNII-F41401512X may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that UNII-F41401512X may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using UNII-F41401512X .
• It is recommended to evaluate the advantage of not breastfeeding while using UNII-F41401512X Vs not using UNII-F41401512X And continue breastfeeding.
• While using UNII-F41401512X Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of Chronic Myeloid Leukemia with positive Philadelphia chromosome. At latest update, relevant published data on excretion into breast milk were not found. Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely. If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, it should be wait for 10 half-lives (T ½). It means that 7 days should be waited before resuming breastfeeding. Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

Although the amount of UNII-F41401512X in milk appears to be small and one breastfed infants apparently experienced no adverse effects during maternal use of UNII-F41401512X, no long-term data are available. Because UNII-F41401512X is 98% bound to plasma proteins, the amounts in milk are likely to be low. However, there is little published experience with UNII-F41401512X during breastfeeding, and an alternate drug may be preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during UNII-F41401512X therapy and for 14 days after the last dose.

A woman with chronic myeloid leukemia received UNII-F41401512X (dosage not stated) for 20 months before pregnancy, throughout pregnancy and continuing during 9 months of breastfeeding (extent not stated). No adverse reactions were reported in her breastfed infant.[2]